

**Table 5. Efficacy results from clinical trials**

	Fondaparinux	Enoxaparin	P value	Relative risk reduction
<b>EPHESUS</b>				
2000				
(hip replacement)				
<b>VTE</b>	37/908 (4%)	85/919 (9%)	<0.0001	-55.9 (-72.8 to -33.1)
<b>Any deep vein thrombosis (DVT)</b>	36/908 (4%)	83/918 (9%)	<0.0001	-56.1 (-73.2 to -32.9)
<b>Proximal DVT</b>	6/922 (0.7%)	23/927 (2%)	0.0021	-73.8 (-95.2 to -24.4)
<b>Distal DVT</b>	30/909 (3%)	67/917 (7%)	<0.0001	-54.8 (74.1 to -27.4)
<b>PENTATHLON</b>				
2000				
(hip replacement)				
<b>VTE</b>	48/787 (6%)	66/797 (8%)	0.099	-26.3 (-52.8 to 10.8)
<b>Distal DVT</b>	34/796 (4%)	54/800 (7%)	0.037	-36.7 (63.1 to 2.4)
<b>Any DVT</b>	44/784 (5.6%)	65/796 (8%)	0.047	-31.3 (-56.8 to -4.8)
<b>PENTAMAKS</b>				
1999				
(knee replacement)				
<b>VTE</b>	45/361 (12.5%)	101/363 (27.8%)	<0.001	55.2 (-36.2 to -70.2)
<b>Any DVT</b>	45/361 (12.5%)	98/361 (27.1%)	<0.001	54.1 (-34.5 to -69.6)
<b>Distal DVT</b>	35/372 (9.4%)	78/366 (21.3%)	<0.001	55.9 (-33.0 to -72.9)
<b>PENTHIFRA</b>				
1999				
(hip fracture)				
<b>VTE</b>	52/626 (8.3%)	119/624 (19.1%)	<0.001	56.4 (-39.0 to -70.3)
<b>Any DVT</b>	49/624 (7.9%)	117/623 (18.8%)	<0.001	58.2 (-41.0 to -71.8)
<b>Distal DVT</b>	42/627 (6.7%)	94/626 (15.0%)	<0.001	55.4 (-34.4 to -71.3)